• Corpus ID: 25135841

Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.

  title={Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.},
  author={J Chen and Sven-Erik Strand and Jan Tennvall and Lars Lindgren and Cecilia Hindorf and Hans Olov Sj{\"o}gren},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={38 12},
  • J. Chen, S. Strand, H. Sjögren
  • Published 1 December 1997
  • Biology
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
UNLABELLED Based on the biodistribution and kinetics of biotinylated 188Re-chimeric BR96 (chiBR96), the enhancement of the tumor-to-normal tissue (T/N) radioactivity ratio using extracorporeal immunoadsorption (ECIA) was evaluated and compared with that of avidin "chase" in colon carcinoma-isografted Brown Norwegian rats. METHODS Extracorporeal immunoadsorption (ECIA) was performed 6 or 12 hr after intravenous administration of biotinylated 188Re-chiBR96. Radioactivity redistribution was… 

Figures and Tables from this paper

Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody

The chase strategy reduces hapten concentration in blood and thus should reduce bone marrow exposure, and the use of two different recognition systems limits possible interference.

Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels.

The method described produced high tumor-to-nontumor ratios at 1 d after injection and may be advantageous for tumor imaging with antibodies and Radiation dosimetry calculations indicate that there is only a slight advantage with this approach for radioimmunotherapy.

Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.

The gal-SA clearance method was compared with the use of 99mTc-F(ab)2 fragments, using the same Ab to carcinoembryonic antigen (CEA), with a colon carcinoma xenograft, and produced substantially higher tumor/non-tumor localization ratios for all tissues except the liver.

Avidin Chase Can Reduce Myelotoxicity Associated with Radioimmunotherapy of Experimental Liver Micrometastases in Mice

Avidin chase effectively reduced the side effects of RIT and should increase the MTD, and treated groups with and without avidin chase showed significant therapeutic effects compared to the non‐treated group.

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.

A novel "extracorporeal affinity adsorption treatment" (ECAT) device (MitraDep) was tested, with which biotinylated and radiolabeled MAbs can be removed from the circulation by passing whole blood over a filter coated with avidin.

Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium‐111–HMFG1–biotin

The aim of the current study was to determine whether ECAT could be used to reduce activity after intraperitoneal (i.p.) administration of indium‐111(111In)–HMFG1–biotin in rats, and to compare the pharmacokinetics of 111In‐ HMFG1 with or without attached biotin after i.p. injection.

Blood Pharmacokinetics of Various Monoclonal Antibodies Labeled with a New Trifunctional Chelating Reagent for Simultaneous Conjugation with 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid and Biotin before Radiolabeling

Different antibodies labeled with the trifunctional chelator 1033 and 111In did not exhibit different blood pharmacokinetics, which means that the pharmacokeretics could be predicted irrespective of the IgG1 antibody chosen.

Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.

A method to predict preferred intervention times and TIs by using pharmacokinetic tracer studies carried out without intervention is presented, and the potential value of cleavable linkers in substantially increasing the TI is highlighted.

Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy

The results showed good reproducibility and dose-dependent toxicity for both radionuclides, indicating that the maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in immunocompetent rats is 1.7 times that for 90Y–BR96 (600 MBq/kg) in rats.



Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA).

Injection of larger amounts of MAb, probably causing a higher degree of tumor saturation, will not necessarily improve the T/N ratio after ECIA.

Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method.

The WBIA method was as effective as ECIA, but technically simpler, safer and more reliable, as compared with extracorporeal immunoadsorption (ECIA).

Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor.

This method may find application in clinical radioimmunoimaging, especially using short half-life radionuclides such as 99mTc and 123I, and using radiolabeled biotinylated antibodies followed by a "chase" avidin injection.

A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy.

This study proves that an important reduction in background activity, and thereby an improvement in the tumor-to-background ratio, can be achieved by using this generally applicable, biotin-avidin ECIA method.

Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.

  • Z. YaoM. Zhang J. Konishi
  • Biology, Chemistry
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1995
Localization of radiolabeled streptavidin in tumors pretargeted with biotinylated MAb could be improved by avidin chase, and this approach may be useful for tumor radioimmunoimaging andRadioimmunotherapy.

Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column.

The feasibility of using extracorporeal immunoadsorption to improve MoA imaging of tumors was demonstrated and tumor-to-blood activity ratios more than doubled, improving by an average of 121% between the pre- and posttreatment image sets.

Optimization of radioiodination and biotinylation of monoclonal antibody chimeric BR96: an indirect labeling using N-succinimidyl-3-(tri-n-butylstannyl)benzoate conjugate.

It was found that 125I-chiBR96 with or without biotinylation had the same stability, immunoreactivity and biodistribution with a high tumor targeting capacity, hence, the ATE conjugate radioiodination method enables the combination of iodination and simultaneous biOTinylation of chiBR96.

Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice.

The biodistribution, pharmacokinetic, and scintigraphic image results suggest that 186Re-labeled NR-LU-10 shows promise as a therapeutic agent for gastrointestinal cancer and in an experimental hepatic metastasis model.